Concepedia

Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure

Mihai Gheorghiade, An Thyssen, Robert Zolynas, Venkatesh Nadar, Barry Greenberg, Mandeep R. Mehra, Xiang Sun, Hong Tian, Alexei N. Plotnikov, Paul Burton

The Journal of Heart and Lung Transplantation · 2010 · 33 citations · 25 references

DOI

Concepts

References

25

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Bengt I. Eriksson, Lars C. Borris, Richard J. Friedman et al. · New England Journal of Medicine · 2008 · 1.4K citations · Full text

, , +15

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty

Michael R. Lassen, Walter Ageno, Lars C. Borris et al. · New England Journal of Medicine · 2008 · 1.3K citations · Full text

, , +17

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

Ajay K. Kakkar, Benjamin Brenner, Ola E. Dahl et al. · The Lancet · 2008 · 1.1K citations · Full text

, , +17

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

Alexander GG Turpie, Michael R. Lassen, Bruce L. Davidson et al. · The Lancet · 2009 · 979 citations

, , +16

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial

J. L. Mega, Eugene Braunwald, Satishkumar Mohanavelu et al. · The Lancet · 2009 · 693 citations

, , +17